Bausch wins US appeal to block Alvogen generic of diarrhea drug [Reuters]
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Reuters
, opens new tab that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen subsidiary Norwich Pharmaceuticals' generic would infringe patents owned by Bausch's Salix Pharmaceuticals. It blocked the U.S. Food and Drug Administration from approving the generic until the last Xifaxan U.S. patent expires in October 2029. Representatives for Bausch and Alvogen did not immediately respond to requests for comment on the decision. Bausch has said the litigation could affect its plans to spin off its eye-care business Bausch + Lomb. Analysts at Jefferies said on Thursday that the decision removes a "key barrier" for the spinoff. Bausch has separately agreed to allow Xifaxan generics from Teva Pharmaceuticals (TEVA.TA) New Tab , opens new tab , Sun Pharmaceuticals (SUN.NS) New Tab , opens new tab and Sandoz (SDZ.S) New Tab , opens new tab starting in 2028 aft
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual MeetingBusiness Wire
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry EyesBusiness Wire
- Bausch + Lomb Co. (NYSE: BLCO) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $18.00. They now have an "outperform" rating on the stock.MarketBeat
BLCO
Earnings
- 2/21/24 - Beat
BLCO
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEF
- 4/26/24 - Form 4
- BLCO's page on the SEC website